A Phase II Trial of Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma

Trial Profile

A Phase II Trial of Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Cyclophosphamide; Topotecan
  • Indications Ewing's sarcoma; Neuroblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
    • 25 Apr 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 25 Apr 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top